Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
Phase II Study of Pazopanib Monotherapy in Patients With Unresectable, Metastatic Neuroendocrine Tumor
To determine the response rate of pazopanib when administered as monotherapy in patients with unresectable neuroendocrine tumor.
Inclusion Criteria:
Exclusion Criteria: